AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02583607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brava
Description: The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it.
Study NCT02465710 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic organ prolapse surgery without mesh
Description: retrospective study
Study NCT02465710 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic organ prolapse surgery with mesh
Study NCT01544153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org.
Study NCT02696018 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic assessment of the diaphragm function
Study NCT01544153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
Study NCT03111498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: theory-based training programme
Description: theory-based training programme for conducting VAD
Study NCT01621750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study NCT01621750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study NCT06019104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition.
Study NCT06019104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
Study NCT02341300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cast Iron Pot
Description: Cast iron pot
Study NCT02341300 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alumnium Pot
Description: Aluminum Skillet
Study NCT01798550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Twice daily dosing
Study NCT03640793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of 6 PPIS implants
Study NCT03879252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
Study NCT03879252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes
Description: Mouthwashes three times a day with a 1.4% baking mouthwash solution.
Study NCT00683371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Specimen collection
Description: 10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
Study NCT00683371 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Specimen collection
Description: 10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
Study NCT01636778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR
Description: TPO receptor agonist to increase platelet count
Study NCT02074865 — intervention group
Intervention type: BIOLOGICAL
Intervention: biological samples
Study NCT04685434 — intervention group
Intervention type: OTHER
Intervention: Shriners Hospital for Children Upper Extremity Evaluation
Description: The interventions are evaluating tools for the functional performance of the upper extremity.
Study NCT01798550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Twice daily dosing
Study NCT02541253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A
Description: A single 0.5mL dose intramuscular injection
Study NCT02541253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Pre-filled Syringe inj.
Description: A single 0.5mL dose intramuscular injection
Study NCT01024387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Study NCT03650881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrogena ® Light Therapy Acne Mask (MASK)
Description: Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
Study NCT03650881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene
Description: Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
Study NCT01988818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Post-Op
Description: wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
Study NCT01988818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard wound dressing
Description: standard wound dressing after hip-knee or spinal surgery
Study NCT02384148 — intervention group
Intervention type: OTHER
Intervention: Circadian rhythm measurement
Study NCT02384148 — intervention group
Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A 2mm diameter skin biopsy is performed by a physician using standard procedure.
Study NCT04369027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: passive leg raising
Description: passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute
Study NCT03986645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR data acquisition
Description: MR data acquisition using CE and non-CE marked pulse sequences.
Study NCT03843268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMPS Gondola
Description: Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
Study NCT03843268 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AMPS Gondola
Description: Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
Study NCT03843268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Gondola
Description: The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
Study NCT03843268 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Gondola
Description: The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
Study NCT04210700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle.
Study NCT04210700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
Study NCT03456843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Study NCT03456843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Study NCT03456843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03456843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03456843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03456843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo cytoreductive radical prostatectomy
Study NCT00397072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZK 219477
Study NCT03008031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CESM with a reduced dose of contrast agent
Study NCT00572156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NutropinAq® (Somatropin [rDNA origin])
Description: rhGH (Somatropin) 45µg/kg once daily injection
Study NCT00572156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
Study NCT00572156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
Study NCT00572156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
Study NCT01459679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (15 mW/cm2)
Description: UVA irradiation for 8 minutes at 15 mW/cm2
Study NCT01459679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (30 mW/cm2)
Description: UVA irradiation for 4 minutes at 30 mW/cm2
Study NCT01057316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 3
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
Study NCT01244568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment DESI
Description: DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
Study NCT02832687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
Study NCT02832687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 100mL of normal saline every 4 hours to a maximum administration of 400mL
Study NCT01143259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopam
Description: The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
Study NCT01143259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 300 mg Polyethylene
Description: The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
Study NCT00099983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
Study NCT00099983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02641080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
Study NCT01459679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (45 mW/cm2)
Description: UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
Study NCT01459679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
Study NCT00003166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT02641080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Compression Device
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
Study NCT00003166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 10mg
Description: HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 10mg combination with Atorvastatin
Description: HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 20mg combination with Atorvastatin
Description: HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 20mg
Description: HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
Study NCT03464682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
Study NCT02752997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist discharge medication services
Description: Included in arm descriptions
Study NCT00463450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynodian® Depot (BAY86-5032)
Description: Injection monthly
Study NCT00463450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY86-4980
Description: orally
Study NCT00066092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 12 mg
Description: Pegfilgrastim 12 mg given once for PBPC mobilization
Study NCT00066092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim given daily for PBPC mobilization
Study NCT00066092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg
Description: Pegfilgrastim 6 mg given once for PBPC mobilization
Study NCT03305679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct provisional technique
Description: The method of implantation will be accomplished directly.
Study NCT03305679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Provisional technique
Description: The method of implantation will be accomplished indirectly.
Study NCT01979653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine alone or dexmedetomidine + midazolam
Study NCT00150631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan
Description: placebo controlled double blind
Study NCT00835406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets 70mg
Description: 1 x 70mg, single dose fasting
Study NCT00835406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax® Tablets 70mg
Description: 1 x 70 mg, single dose fasting
Study NCT00663936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA
Description: 224 mg T-817 MA once daily
Study NCT00663936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT01678326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Rendezvous or direct intervention
Study NCT01678326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced ERCP Biliary Access Techniques
Study NCT03011216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive emotional cognitive control training
Description: Is supposed to train ability to continuously update emotional material in working memory.
Study NCT03011216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive non-emotional feature match task
Description: Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
Study NCT03443466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Using loss of resistance technique and electrical stimulation
Study NCT03443466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance (LOR)
Description: Using loss of resistance technique only
Study NCT00127673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.